Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,908 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.
Kasai T, Mori K, Nakamura Y, Seki N, Ichikawa Y, Saito H, Kondo T, Nishikawa K, Otsu S, Bessho A, Tanaka H, Yamaguchi H, Kaburagi T, Imai H, Mori K, Ohtake J, Okamoto H. Kasai T, et al. Among authors: yamaguchi h. Cancer Med. 2023 Jul;12(14):14988-14999. doi: 10.1002/cam4.6135. Epub 2023 May 24. Cancer Med. 2023. PMID: 37226421 Free PMC article. Clinical Trial.
Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells.
Nakano H, Nakamura Y, Soda H, Kamikatahira M, Uchida K, Takasu M, Kitazaki T, Yamaguchi H, Nakatomi K, Yanagihara K, Kohno S, Tsukamoto K. Nakano H, et al. Among authors: yamaguchi h. Cancer. 2008 Mar 1;112(5):1122-30. doi: 10.1002/cncr.23285. Cancer. 2008. PMID: 18219662 Free article.
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, Kohno S. Yamaguchi H, et al. Cancer Chemother Pharmacol. 2011 Feb;67(2):331-8. doi: 10.1007/s00280-010-1325-x. Epub 2010 Apr 17. Cancer Chemother Pharmacol. 2011. PMID: 20401612 Clinical Trial.
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
Fukuda M, Nakamura Y, Kinoshita A, Soejima Y, Yamaguchi H, Ikeda T, Izumikawa K, Takatani H, Fukuda M, Soda H, Hayashi N, Tsukamoto K, Oka M, Kohno S. Fukuda M, et al. Among authors: yamaguchi h. Cancer Chemother Pharmacol. 2012 Nov;70(5):645-51. doi: 10.1007/s00280-012-1952-5. Epub 2012 Aug 22. Cancer Chemother Pharmacol. 2012. PMID: 23010852 Clinical Trial.
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T, Fukuda M, Nakamura Y, Kinoshita A, Senju H, Nakano H, Kitazaki T, Ogawara D, Taniguchi H, Motoshima K, Yamaguchi H, Nakatomi K, Shimada M, Nagashima S, Tsukamoto K, Kohno S; Nagasaki Thoracic Oncology Group. Ikeda T, et al. Among authors: yamaguchi h. Cancer Chemother Pharmacol. 2014 Sep;74(3):497-502. doi: 10.1007/s00280-014-2527-4. Epub 2014 Jul 18. Cancer Chemother Pharmacol. 2014. PMID: 25034978 Free article. Clinical Trial.
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Soda H, Ogawara D, Fukuda Y, Tomono H, Okuno D, Koga S, Taniguchi H, Yoshida M, Harada T, Umemura A, Yamaguchi H, Mukae H. Soda H, et al. Among authors: yamaguchi h. Thorac Cancer. 2019 Feb;10(2):341-346. doi: 10.1111/1759-7714.12952. Epub 2018 Dec 23. Thorac Cancer. 2019. PMID: 30582295 Free PMC article. Clinical Trial.
4,908 results